Effect of Inhaled Corticosteroids on Glycemic Status

Francis Egbuonu 1, Farrah A Antonio 1, Mahamood Edavalath*, 2
1 Department of Medicine, University Hospital of North Staffordshire, ST4 6QG, UK
2 Department of Endocrinology & Diabetes, University Hospital of North Staffordshire, ST4 6QG, UK

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 5814
Abstract HTML Views: 1863
PDF Downloads: 806
Total Views/Downloads: 8483
Unique Statistics:

Full-Text HTML Views: 2491
Abstract HTML Views: 1036
PDF Downloads: 558
Total Views/Downloads: 4085

Creative Commons License
© Egbuonu et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Department of Endocrinology, Royal Stoke University Hospital, Stoke-on-Trent, ST4 6QG, UK; E-mail:


Although the dysglycemic effects of systemic glucocorticoid therapy are well known, the effect of inhaled corticosteroids (ICS) on carbohydrate metabolism is still a subject of debate. The systemic bioavailability of ICS is claimed to be minimal and the side effects negligible. However, some large retrospective cohort studies showed a definite association between ICS use and incident diabetes or worsening glycemic control in pre-existing diabetes. There are no professional-body recommended guidelines on the diagnosis and management of steroid-induced diabetes for the general population. This review aims to evaluate the systemic dysglycemic effect of ICS treatment and to propose a management algorithm.

Keywords: Diabetes control, diabetes mellitus, dysglycemic status, hyperglycemia, inhaled corticosteroids (ICS), steroid-induced diabetes..